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Mitogen-activated protein kinases (MAPKs), also known as
extracellular signal-regulated kinases (ERK1/2), are essential
components of the MAPK signalling pathway. MAPKs are acti-
vated in response to various stimuli, including growth factors,
cytokines, hormones and neurotransmitters, and their activities are
a determining factor for cell proliferation and differentiation
(Blenis, 1993; Stevenson et al, 1994; Marshall, 1995). The activa-
tion of ERK1/2 is the result of the sequential activation of a series
of upstream kinases, including Raf-1 and MEK (Cobb and
Goldsmith, 1995). Activation of ERK1/2 requires dual phosporyl-
ation on threonine and tyrosine residues of the specific peptide
motif, Thr–Glu–Tyr (Zheng and Kuan, 1993). The phosphoryla-
tion of ERK1/2 is a reversible process which is mediated by dual
specific threonine–tyrosine phosphatases like MAPK phosphatase
3 (MKP-3) (Groom et al, 1996). Activated MAPKs transmit their
signals into the nucleus for activation of target transcription
factors such as c-Jun, c-Fos (Lange-Carter et al, 1993) and Elk-1
(Marais et al, 1993). Accurate regulation of MAPK signal trans-
duction is essential for normal cell growth control, and abnormali-
ties in the components of the MAPK pathway are often observed
in various human cancers (Owen et al, 1984; Bos, 1989; Slamon
et al, 1989; Fearon and Vogelstein, 1990; Janes et al, 1994).
Although ERK1/2 are key components in the MAPK pathway, the
relationship between abnormalities of ERK1/2 and human cancers
has not been well characterized. Hyper-expression and activation
of ERK1/2 MAPKs have recently been reported in several human
cancers, including breast carcinomas, leukaemia and renal cell
carcinomas (Oka et al, 1995; Sivaraman et al, 1997; Towatari et al,
1997). However, it is not known whether these are generalized
characteristics for every type of cancer.
Tumorigenesis of the colon is a multistep process including
various genetic alterations of oncogenes (K-ras, src and myc) and
tumour suppressor genes (APC, p53 and DCC etc.) (Fearon and
Vogelstein, 1990; Simon et al, 1994; Kinzler and Vogelstein,
1996). The K-ras gene mutations, which appear in 50% of inter-
mediate adenomas (greater than 1 cm), are one of the major causes
of colon carcinogenesis, suggesting that MAPK activation is
required for tumour progression (Kinzler and Vogelstein, 1996).
Therefore, it is possible that hyper-activation of ERK1/2 MAPKs
may exist in colorectal tumours.
In this study, we examined the status of ERK and MEK kinases
in colorectal specimens to elucidate the relationship between
colorectal carcinogenesis and the MAPK signalling pathway.
Here, we report unusual differential regulation of the MAPK
pathway during colorectal tumorigenesis, suggesting possible
roles of the ERK pathway in both positive and negative growth
control.
MATERIALS AND METHODS
Human tissues and patient information
A total of 21 colorectal carcinomas and seven adenomas (several
of them had different paired adenomas) and adjacent paired
Differential regulation of MAP kinase cascade in human
colorectal tumorigenesis
K-S Park1,2, N-G Kim3, JJ Kim3, H Kim3, YH Ahn1,2 and K-Y Choi1,2
1Department of Biochemistry and Molecular Biology, 2Institute of Genetic Sciences and 3Department of Pathology, Yonsei University College of Medicine,
Seoul 120-752, Korea
Summary Hyper-activation of mitogen-activated protein kinase (MAPK) has recently been reported in several human cancers and activation
of MAPK in those cancers may be associated with carcinogenesis through aberrant cell proliferation. To understand the roles of the MAPK
pathway in colorectal tumorigenesis, we examined the status of extracellular signal-regulated protein kinases (ERK1/2) in 21 colorectal
tumour specimens and compared it with that of paired normals. The specific MAPK activities were two- to tenfold lower in 71% (15 out of
21 cases) of colorectal tumours compared to those in paired normals. The individual MAPK kinase (MEK) correlated with MAPK activities
(P = 0.006). Reduction of the MAPK and MEK activities in colorectal tumours was also observed in adenomas. These results suggested that
down-regulation of the MAPK cascade may be caused by early genetic event(s) and that it may be related to the loss of normal growth
control. Although MAPK activities were down-regulated both in adenomas and carcinomas, activities of the MAPKs in carcinomas were higher
than those of paired adenomas. These results suggested that MAPK activities may be increased in the adenoma-to-carcinoma sequence and
that it may play a role in the tumour progression. Observation of the differential regulation of MAPK activities in colorectal tumorigeneis
suggested roles for the MAPK pathway in both positive and negative controls of cell growth. © 1999 Cancer Research Campaign
Keywords: colorectal cancer; extracellular signal regulated kinase; Ras; MEK; Raf-1
1116
British Journal of Cancer (1999) 81(7), 1116–1121
© 1999 Cancer Research Campaign
Article no. bjoc.1999.0817
Received 9 February 1999
Revised 6 May 1999
Accepted 10 May 1999
Correspondence to: K-Y Choi, Department of Biochemistry and Molecular
Biology, Yonsei University College of Medicine, 134 Shinchon-Dong
Seodemun-Gu, Seoul 120-752, KoreaInhibition of MAP kinase activities in human colorectal adenocarcinomas 1117
British Journal of Cancer (1999) 81(7), 1116–1121 © 1999 Cancer Research Campaign
normal mucosa tissues from 21 patients, as well as two adenoma
and paired normal mucosa from a familial adenomatous polyposis
(FAP) patient, were included in this study. This work was
performed after approval by the Human Investigation Committee
of the Yonsei University College of Medicine. All tissue donors
agreed to provide their samples for this study. The tissues from
surgically resected specimens were fractionated separately for
biochemical analysis and stored at –80°C. Five breast tissue speci-
mens of each cancer and paired normal were also prepared in a
similar way. Information from the Yonsei University Tumor
Registry and chart review was obtained to determine the demo-
graphics and tumour sites of the patients: 14 were at stage 2 and
seven were at stage 3 (Table 1). The six carcinomas located prox-
imal to the splenic flexure were classified as right-sided, and the
15 distal to the splenic flexure as left-sided. The genetic defects
reported in colorectal cancers were also observed in our cases with
similar frequencies. Microsatellite instability of tumours was
observed in six of 21 cases (29%), and p53 mutations (analysed by
SSCP of exon 5–9) were observed in 13 of 21 cases (62%).
Furthermore, 52% (11 of 21 cases) of K-ras had a mutation in
codon 12 or 13.
Extract preparation
Frozen tissue samples were pulverized in liquid nitrogen and the
resultant powder was dissolved in ice-cold lysis buffer (70 mM
b-glycerophosphate pH 7.2, 1 mM each meta- and ortho-vanadate,
2m M magnesium chloride (MgCl2), 1 mM EGTA, 1 mM dithio-
threitol (DTT), 0.5% Triton X-100, 0.2 mM phenylmethyl-
sulphonyl fluoride (PMSF) and 5 mg ml–1 each of pepstatin A,
chymostatin, leupeptin and peptin) and kept on ice for 20 min. The
samples were sonicated for 30 s and unbroken cellular debris was
removed by centrifugation at 23 000 g for 10 min. The supernatant
was further cleared by a subsequent centrifugation. Samples were
immediately aliquoted and frozen at – 80°C. Protein concentra-
tions were determined with a Bio-Rad protein assay method
(Bio-Rad Laboratories, Richmond, CA, USA).
In vitro MAPK assays
MAPK assays were performed by a non-radioactive method
developed by New England Biolabs Inc. (Beverly, MA, USA) as
recommended by the manufacturer. MAPKs were immunoprecipi-
tated from 300 mg of tissue extract with phospho-specific ERK1/2
MAPK (Thr202/Tyr204) monoclonal antibody, and kinase assays
were performed in the presence of ATP and a GST-fused physio-
logical substrate, Elk-1. Detection of the phospho-Elk-1 protein
was performed by Western blot analysis using phospho-specific
Elk-1 (Ser383) antibody. The phospho Elk-1 antibody specifically
recognizes Elk-1 protein with phosphorylation at Ser383.
Western blot analysis
The lysates containing 40–100 mg of protein were subjected to 8%,
10%, or 12% sodium dodecyl sulphate polyacrylamide gel
electrophoresis (SDS-PAGE; acrylamide:bis-acrylamide at a ratio
of 29:1) and proteins were transferred onto a Protran Nitro-
cellulose Membrane (Schleicher and Schuell Corporation, Dassel,
Table 1 Inhibition of ERK and MEK activities in human colorectal tumour
Tumour Relative MAPK inhibition
Case Grade Stage In vitro Phosphorylationb Relative MAPK MEK
(differentiation) kinase assaya expressionc inhibitiond
1 Well 3 (T3N0M0) 10.42 4.8 1.29 ND
2 Well 2 (T3N0M0) 6.37 3.2 1.0 +
3 Moderate 2 (T2N0M0) 6.19 5.0 1.1 +
4 Moderate 2 (T3N0M0) 6.19 4.0 0.93 +
5 Moderate 2 (T3N0M0) 5.27 3.0 0.9 +
6 Moderate 2 (T3N0M0) 5.05 2.5 1.08 +
7 Moderate 3 (T3N0M0) 5.05 5.0 0.87 +
8 Moderate 3 (T3N1M0) 4.8 6.4 ND +
9 Moderate 2 (T3N0M0) 3.8 ND 1.0 +
10 Moderate 2 (T3N0M0) 3.5 6.8 1.3 +
11 Well 3 (T3N2M0) 3.16 3.1 ND +
12 Poor 3 (T3N1M0) 3.16 3.0 1.07 +
13 Moderate 2 (T3N0M0) 3.0 3.3 1.5 +
14 Moderate 2 (T3N0M0) 2.4 2.0 1.0 +
15 Moderate 2 (T3N0M0) 2.8 1.0 1.5 –
16 Poor 2 (T2N0M0) 1.53 1.5 1.5 –
17 Moderate 2 (T3N0M0) 1.5 1.5 1.14 –
18 Moderate 3 (T4N1M0) 1.5 0.5 1.32 +
19 Moderate 3 (T3N2M0) 1.15 1.5 1.01 –
20 Moderate 2 (T3N0M0) 1.01 1.0 0.67 –
21 Moderate 2 (T2N0M0) 1 2.0 1.19 –
aRelative MAPK inhibitions were obtained by N/C ratio of MAPK activity obtained by quantitation of phospho Elk-1 bands produced by in vitro kinase assay (see
Materials and Methods). Representative cases of the assay are shown in Figure 1. bRelative MAPK inhbitions were obtained by N/C ratio of phospho-ERK1/2
band intensities produced by Western blot analysis. Representative cases of the assay are shown in Figure 2A. cRelative MAPK expressions were obtained by
N/C ratio of MAPK band intensities produced by Western blot analysis. Representative cases of the assay are shown in Figure 2B. dRelative MEK inhibition
values were obtained by N/C ratio of specific MEK activities (phospho-MEK/MEK band intensities) produced by Western blot analysis. Representative cases of
the assay are shown in Figure 4. The cases which show N/T ratio higher than 2 were recorded as positive. ‘ND’ represent not determined data.Germany). Blots were blocked in 20 mM Tris–Cl, pH 7.5, 150 mM
sodium chloride (NaCl), 0.05% Tween-20 (TBST) containing 5%
non-fat Carnation milk. Immunoblots were then washed with
TBST and incubated 2 h at room temperature or overnight at 4°C
with TBST milk containing appropriate amounts of primary anti-
bodies. The blots were then washed and incubated with TBST
milk containing appropriate secondary antibody for 1–2 h. After
washing, the blots were developed with Amersham ECL kit
(Amersham International, Buckinghamshire, UK). Quantitation of
Western bands were made by densitometric scanning of the films
by using a Bio-Rad imager system (Model GS-525) with analysing
software (Molecular Analyst Software version 1.5, BioRad). MEK
inhibition was considered as positive when the specific MEK
activity of a tumour was lower (> twofold) than that of a paired
normal (Table 1).
Antibodies
The following antibodies were purchased and used for Western
blot analysis and immunoprecipitation. Anti-MAPK rabbit poly-
clonal antibody was purchased from Stratagene (La Jolla, CA,
USA). Phospho-specific MAPK antibody (raised against synthetic
phospho-tyrosine peptide corresponding to residues 196 to 209
[DHTGFL TEY(P) VATRWC) of human ERK2] was purchased
from New England Biolabs Inc. Phospho-specific MEK antibody
(produced by immunizing rabbits with synthetic phospho-
Ser217/221 peptide) was also purchased from New England
Biolabs, Inc. Anti-MEK antibody was purchased from
Transduction Laboratories (Lexington, KY, USA). Horseradish
peroxidase-conjugated secondary antibodies were purchased from
New England Biolab Inc. or Transduction Laboratories.
Statistical analysis
Linear correlation between two variables of MAPK inhibition (in
vitro kinase assay versus phospho-ERK1/2) was determined by
calculating Pearson’s correlation coefficient. The Wilcoxon’s rank
sum tests were performed to determine the relationships between
MAPK inhibition and phospho-MEK. P-values less than 0.05 were
considered to be statistically significant. Data were analysed with
SPSS statistical software package (SPSS Inc., Chicago, IL, USA).
RESULTS
Inhibition of MAPK activity in colorectal tumour
To elucidate the relationship between MAPK and colorectal
tumours, we measured ERK1/2 MAPK activities in 21 human
colorectal tumour tissues and paired normals. The ERK1/2 MAPK
assays were performed using Elk-1 as a substrate (Marais et al,
1993). In addition, MAPK activity was also analysed alternatively
by measuring the level of phospho-ERK1/2 (Oka et al, 1995;
Sivaraman et al, 1997). To our surprise, MAPK activities were
significantly lower in 71% of the tumours (15 of 21 cases)
compared to those in paired normals (Table 1). Nine representative
cases are shown in Figure 1. The degree of inhibition (N/C ratio 
> 2) varied from tumour to tumour, with a two- to tenfold variation
(Table 1). The phospho-ERK1/2 MAPKs were also lower in 70%
of tumours (14 of 20 cases), and the levels were linearly correlated
with MAPK activities (P = 0.002; Table 1). Five representative
cases are shown in Figure 2A. However, the levels of ERK1/2
proteins were similar in all cases including both tumours and
normals (Figure 2B and Table 1). The inhibition of ERK1/2
activities did not significantly correlate with the location, grade,
stage and other pathological states of the tumours (see Materials
and Methods).
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Figure 1 Relative MAPK activities in representative colorectal tumours and
paired normals. (A) MAPK activity was determined by the ability of phospho-
specific MAPK (Thr202/Tyr204) antibody-immunoprecipitates to
phosphorylate Elk-1 as described in Materials and Methods. The phospho-
Elk-1 was detected by Western blot analysis using phospho-specific Elk-1
(Ser383) antibody. Numbers above the figure represent case numbers. N
represents normal tissue and C represents carcinoma tissue. The M
represents biotinylated protein-sized marker, and Con represents Elk-1
protein phosphorylated by activated P-ERK1/2. (B) Quantitative comparison
of MAPK activities. MAPK activities were quantitated by densitometric
scanning of ECL film as described in Materials and Methods. Numbers above
the bars represent fold-inhibition calculated by N/C ratioActivation MAPK activity in breast carcinoma
Since the low MAPK activity in the colorectal tumours was
unexpected, we also checked ERK1/2 activities in five breast
carcinomas and five normal tissues from the same patient by
checking phospho-ERK1/2 levels (Sivaraman, 1997). In contrast
to the cases of colorectal tumour, ERK activities were increased in
all four breast carcinomas compared to those of paired normals
(Figure 3A). In addition, two of five cases (nos 4 and 5) of breast
carcinomas showed overexpression of ERK (Figure 3B).
Inhibition of MEK in colorectal tumour
To determine a source for the inhibition of ERK1/2 activities, we
measured activities of an upstream kinase, MEK, by measuring the
levels of phospho-MEK. The phospho-MEK protein levels were
also lower in 70% (14 out of 20 cases) of the colorectal tumours
(Table 1). Seven representative cases of these are shown in
Figure 4. The MEK protein levels were similar or slightly higher in
normals, except case no. 20, which showed a two- to threefold
higher protein level in normal (Figure 4). Inhibition of specific
MEK activities was correlated with the level of MAPK activity
(P = 0.0006) (Table 1).
Inhibition and activation of ERK1/2 and MEK activities
during colorectal tumorigenesis
Due to the unexpected depression of ERK1/2 activities in
colorectal carcinomas, we were interested in ERK1/2 activities in
the adenomas and measured the MAPK activities in seven
adenomas by measuring phospho-ERK1/2 protein levels. The size
of adenomas varied from 0.4 to 2.8 cm (Figure 5). Several cases
had multiple-sized adenomas (Figure 5; nos 22, 13 and 2). In
adenomas, ERK1/2 activities were also significantly down-
regulated in six of seven cases (nos 10, 15, 8, 11, 13 and 2) and the
ERK1/2 activities in adenomas were even lower than those in
carcinomas, except in case nos 8 and 13 (Figure 5). The ERK1/2
activities in case no. 22, a patient with FAP, were significantly
lower even in normal samples. Interestingly, the ERK activities in
carcinomas were higher than paired adenomas in four (nos 10, 15,
11 and 2) out of six cases which showed down-regulation of
enzyme activities in adenomas. The variations of phospho-
ERK1/2 in different steps of tumorigenesis mostly correlated well
with those of phospho-MEK activities, and several available cases
including the normal and 0.8 cm adenoma in the FAP are shown in
Figure 5. Although phospho-ERK and phospho-MEK levels were
variable, ERK and MEK levels were mostly equivalent in the
different colorectal specimens.
Inhibition of MAP kinase activities in human colorectal adenocarcinomas 1119
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Figure 2 Levels of MAPKs in the representative colorectal tumours and
paired normals. (A) The phospho-ERK proteins were detected by Western
blot analysis by using phospho-specific MAPK (P-ERK1/2) antibody. (B) The
ERK1/2 proteins were detected by Western blot analysis by using ERK1/2
polyclonal antibody. N and C also represent normal and carcinoma
respectively
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Figure 3 MAPK activities and the expression of MAPKs in breast tumours
and paired normals. (A) MAPK activity was detected by Western blot
analysis by using phospho-specific ERK1/2 antibody. (B) The ERK proteins
were detected by Western blot analysis by using ERK1/2 polyclonal antibody.
Numbers above the lanes represent case numbers. C represents tissue from
breast carcinoma patients, and N represents normal tissue from the patient
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Figure 4 Inhibition of MEK activity in representative colorectal tumours and
paired normals. MEK activity was monitored by Western blot analysis using
phospho-specific MEK polyclonal antibody. MEK protein levels were detected
by Western blot analysis using MEK polyclonal antibody. Numbers represent
case numbers. N and C also represent normal and carcinoma respectively1120 K-S Park et al
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DISCUSSION
The ras gene product, Ras, functions upstream of Raf-1 in the
MAPK pathway and its status is an important factor in the activa-
tion of ERK1/2 (Blenis, 1993; Marais et al, 1993). Point mutations
of the ras oncogene cause the Ras protein to remain in an active
state, continuously sending signals downstream (Vogel et al,
1988). Like other cancers, overexpression and mutations of the ras
gene are frequently observed in colorectal tumours (Spandidos,
1984; Vogelstein et al, 1988; Ahnen et al, 1998). Therefore, we
questioned the activation status of ERK1/2 MAPKs in colorectal
cancer. Interestingly, ERK1/2 activities were significantly lower in
71% of tumours compared to those in paired normal mucosa
tissues. However, ERK1/2 protein levels were similar in all cases,
including both cancers and paired normals. Therefore, the differ-
ential ERK1/2 activities may be due to the modification of protein,
phosphorylation for example, rather than differential gene expres-
sion or protein stability. ERK activities in colorectal cells were
mostly proportional to the protein levels of phospho-ERKs
(Table 1). Low ERK activities in our colorectal tumours were
surprising considering that ERK activities are increased in breast
carcinomas, renal cell carcinomas and leukaemia (Oka et al, 1995;
Sivaraman et al, 1997; Towatari et al, 1997). Therefore, we also
checked the status of ERKs in breast carcinoma tissues where
increased ERK activities were observed (Sivaraman et al, 1997).
The levels of phospho-ERK were significantly higher in all four
cases of breast carcinoma compared with those in paired normals.
Similar to the previous study, the ERK protein levels in breast
carcinomas were also elevated in several cases, which were not
observed in any of our 21 colorectal carcinomas. Therefore,
depressed activities of ERKs in colorectal cancer are not a
common feature of all cancers.
To investigate the source of ERK inactivation in colorectal
tumours, we checked the activities in the upstream signalling
components MEK by monitoring the status of protein modifica-
tions. The MEK activities measured by phospho-MEK
immunoblot were mostly lower in colorectal tumours, as were the
cases of MAPK activities. Furthermore, patterns of MEK activa-
tion in adenoma-to-carcinoma sequences were also in agreement
with those of ERK activation. Therefore, a signal for ERK
inhibition may come from upstream MEK. The inhibition of
ERK activities in a colorectal tumour is highly analogous to that
of PKC. The activities of protein kinase C (PKC) were also
reduced in human colon carcinoma when those were compared
with paired normal mucosa (Guillem et al, 1987; Kopp et al,
1991). In addition, the decrease in PKC activity in adenomas was
also similar to the case of MAPK activity, in that it was related to
the occurrence of early premalignant stages of intestinal mucosa
(Kopp et al, 1991). Although limited by the number of cases,
down-regulation of ERK activities in adenocarcinoma and
correlation of the ERK activities with PKC activities was observed
in a previous study (Attar et al, 1996). In addition, reduced MAPK
activity in human gastric adenocarcinoma was also reported
(Atten et al, 1995).
Physiological roles of the high ERK activities in normal
colorectal mucosa were not understood. However, our results of
the reduction of ERK and MEK activities in early adenomas
suggested that ERK activities in normal colonic epithelial cells
may be involved in normal cellular growth control (Atten et al,
1995), and that the early genetic events in tumorigenesis could
result in the lack of growth control, which may be related to the
reduction of ERK activities. A role of ERK activation in growth
inhibition rather than growth stimulation were recently reported
(Pumiglia and Decker, 1997; Sewing et al, 1997). Down-regula-
tion of the ERK pathway in early adenoma may result in the
activation of a circumventing mechanism for aberrant cell growth
like c-MYC overexpression (Alexander et al, 1989; Marcus et al,
1992; He et al, 1998), and that together with secondary genetic
events like ras mutation may promote the progression to malig-
nancy. In colorectal tumorigenesis, most K-ras mutations occurred
in the mid-adenoma (larger than 1 cm) stages of tumorigenesis and
a ras mutation may still be required in the progression to colorectal
carcinoma (reviewed in Fearon and Vogelstein, 1990; Kinzler and
Vogelstein, 1996). Therefore, it is possible that an increase of
ERK and MEK activities in adenoma-to-carcinoma sequence of
colorectal tumorigenesis may be caused by a ras mutation. A role
of ras mutations in tumour progression, not in the initiation, was
also suggested (Kinzler and Vogelstein, 1996). Dramatic down-
regulation of ERK1/2 and MEK activities in the early stages of
adenoma suggest the possible application of this phenomenon for
early diagnosis of colorectal tumour.
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Figure 5 Differential MAPK and MEK activities in colorectal tumorigenesis.
The ERK1/2 and MEK activities in representative adenomas, paired normals
and carcinomas were detected by Western blot analysis by using phospho-
specific ERK1/2 and MEK antibodies. The ERK and MEK proteins were
detected by Western blot analysis by using ERK1/2 or MEK antibody.
Numbers in brackets represent the size of adenomas. Numbers above the
cases represent case numbers. Each N, A and C denotes normal, adenoma
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